Controlled substanceDrug codeScheduleGamma Hydroxybutyric Acid.2010ITetrahydrocannabinols7370IAmphetamine1100IILisdexamfetamine1205IIMethylphenidate1724IIANPP (4-Anilino-N- phenethyl-4-piper- idine).8501IICodeine9050IIOxycodone9143IIHydrocodone9150IIMethadone9250IIOripavine9330IIOpium extracts9610IIOpium fluid extract9620IIOpium, powdered9639IIOxymorphone9630IIOpium, powdered9630IIOpium, powdered9630IIOpium, powdered9630IIOpium, powdered9630IIOpium, pomphone9668IIOpium, pomphone9668II			
Acid.TetrahydrocannabinolsTetrahydrocannabinols7370Amphetamine1100Lisdexamfetamine1205IIMethylphenidateANPP (4-Anilino-N- phenethyl-4-piper- idine).8333Phenylacetone8501Phenylacetone9050IIOxycodone9150IIHydromorphone9150Hydrocodone9193IIMethadone9250IIOripavine9330IIThebaineOpium extracts9610Opium fluid extract9630IIOpium, powdered9630IIOripavinoe9639IIOpium, powdered9630IIOpium, powdered9639IIOxymorphone9668II	Controlled substance		Schedule
Amphetamine    1100    II      Lisdexamfetamine    1205    II      Methylphenidate    1724    II      ANPP (4-Anilino-N-    8333    II      phenethyl-4-piper-    idine).    8501    II      Codeine    9050    II      Oxycodone    9143    II      Hydrocodone    9193    II      Methadone    9250    II      Morphine    9300    II      Oripavine    9333    II      Opium extracts    9610    II      Opium fluid extract    9630    II      Opium, powdered    9639    II      Oxymorphone    9652    II		2010	I
Amphetamine    1100    II      Lisdexamfetamine    1205    II      Methylphenidate    1724    II      ANPP (4-Anilino-N-    8333    II      phenethyl-4-piper-    idine).    8501    II      Codeine    9050    II      Oxycodone    9143    II      Hydrocodone    9193    II      Methadone    9250    II      Morphine    9300    II      Oripavine    9333    II      Opium extracts    9610    II      Opium fluid extract    9630    II      Opium, powdered    9639    II      Oxymorphone    9652    II	Tetrahydrocannabinols	7370	1
Methylphenidate    1724    II      ANPP (4-Anilino-N-phenethyl-4-piper-idine).    8333    II      Phenylacetone    8501    II      Codeine    9050    II      Oxycodone    9143    II      Hydromorphone    9150    II      Hydrocodone    9193    II      Methadone    9250    II      Morphine    9300    II      Oripavine    9333    II      Opium extracts    9610    II      Opium fluid extract    9620    II      Opium, powdered    9639    II      Oxymorphone    9652    II      Noroxymorphone    9668    II	Amphetamine	1100	П
ANPP (4-Anilino-N-phenethyl-4-piper-idine).    8333    II      Phenylacetone    8501    II      Codeine    9050    II      Oxycodone    9143    II      Hydromorphone    9150    II      Hydrocodone    9193    II      Methadone    9250    II      Morphine    9300    II      Oripavine    9333    II      Opium extracts    9610    II      Opium fluid extract    9630    II      Opium, powdered    9639    II      Oxymorphone    9639    II      Oxymorphone    9652    II	Lisdexamfetamine	1205	П
phenethyl-4-piper- idine).      8501      II        Phenylacetone      9050      II        Codeine      9050      II        Oxycodone      9143      II        Hydromorphone      9150      II        Hydrocodone      9193      II        Methadone      9250      II        Morphine      9300      II        Oripavine      9333      II        Opium extracts      9610      II        Opium fluid extract      9620      II        Opium, powdered      9639      II        Opium, powdered      9639      II        Oxymorphone      9652      II        Noroxymorphone      9668      II	Methylphenidate	1724	П
idine).    8501    II      Phenylacetone    8501    II      Codeine    9050    II      Oxycodone    9143    II      Hydromorphone    9150    II      Hydrocodone    9193    II      Methadone    9250    II      Morphine    9300    II      Oripavine    9333    II      Opium extracts    9610    II      Opium fluid extract    9620    II      Opium, powdered    9639    II      Opium, powdered    9639    II      Oxymorphone    9652    II      Noroxymorphone    9668    II	ANPP (4-Anilino-N-	8333	П
Phenylacetone      8501      II        Codeine      9050      II        Oxycodone      9143      II        Hydromorphone      9150      II        Hydrocodone      9193      II        Methadone      9250      II        Morphine      9300      II        Oripavine      9333      II        Opium extracts      9610      II        Opium fluid extract      9630      II        Opium, powdered      9639      II        Oxymorphone      9652      II        Noroxymorphone      9668      II	phenethyl-4-piper-		
Codeine      9050      II        Oxycodone      9143      II        Hydromorphone      9150      II        Hydrocodone      9193      II        Methadone      9250      II        Morphine      9300      II        Oripavine      9330      II        Thebaine      9333      II        Opium extracts      9610      II        Opium fluid extract      9630      II        Opium, powdered      9639      II        Oxymorphone      9652      II		8501	11
Oxycodone      9143      II        Hydromorphone      9150      II        Hydrocodone      9193      II        Methadone      9250      II        Morphine      9300      II        Oripavine      9330      II        Thebaine      9333      II        Opium extracts      9610      II        Opium fluid extract      9630      II        Opium, powdered      9639      II        Opium, powdered      9652      II        Noroxymorphone      9668      II	Codeine	9050	11
Hydromorphone    9150    II      Hydrocodone    9193    II      Methadone    9250    II      Morphine    9300    II      Oripavine    9330    II      Thebaine    9333    II      Opium extracts    9610    II      Opium fluid extract    9620    II      Opium, powdered    9630    II      Opium, powdered    9639    II      Oxymorphone    9652    II		9143	11
Hydrocodone    9193    II      Methadone    9250    II      Morphine    9300    II      Oripavine    9330    II      Thebaine    9333    II      Opium extracts    9610    II      Opium fluid extract    9630    II      Opium, powdered    9639    II      Opium, powdered    9652    II      Noroxymorphone    9668    II		9150	11
Methadone      9250      II        Morphine      9300      II        Oripavine      9330      II        Thebaine      9333      II        Opium extracts      9610      II        Opium fluid extract      9620      II        Opium tincture      9630      II        Opium, powdered      9639      II        Oxymorphone      9652      II        Noroxymorphone      9668      II	Hydrocodone	9193	П
Oripavine      9330      II        Thebaine      9333      II        Opium extracts      9610      II        Opium fluid extract      9620      II        Opium fluid extract      9630      II        Opium tincture      9630      II        Opium, powdered      9639      II        Oxymorphone      9652      II        Noroxymorphone      9668      II	Methadone	9250	П
Oripavine      9330      II        Thebaine      9333      II        Opium extracts      9610      II        Opium fluid extract      9620      II        Opium tincture      9639      II        Opium, powdered      9639      II        Oxymorphone      9652      II        Noroxymorphone      9668      II	Morphine	9300	П
Thebaine      9333      II        Opium extracts      9610      II        Opium fluid extract      9620      II        Opium tincture      9630      II        Opium, powdered      9639      II        Oxymorphone      9652      II        Noroxymorphone      9668      II		9330	П
Opium fluid extract      9620      II        Opium tincture      9630      II        Opium, powdered      9639      II        Oxymorphone      9652      II        Noroxymorphone      9668      II		9333	П
Opium tincture      9630      II        Opium, powdered      9639      II        Oxymorphone      9652      II        Noroxymorphone      9668      II	Opium extracts	9610	П
Opium tincture      9630      II        Opium, powdered      9639      II        Oxymorphone      9652      II        Noroxymorphone      9668      II	Opium fluid extract	9620	П
Oxymorphone9652IINoroxymorphone9668II		9630	П
Oxymorphone9652IINoroxymorphone9668II	Opium, powdered	9639	П
Noroxymorphone		9652	П
Fastand 0001 II		9668	П
Fentanyi 9801   II	Fentanyl	9801	П

The company plans to manufacture the listed controlled substances in bulk for conversion to other controlled substances and sales to its customers for dosage form development, clinical trials and use in stability qualification studies.

In reference to drug codes 7360 (Marihuana), and 7370

(Tetrahydrocannabinols), the company plans to bulk manufacture these drugs as synthetic. No other activities for these drug codes are authorized for this registration.

# Claude Redd,

Acting Deputy Assistant Administrator. [FR Doc. 2023–18043 Filed 8–21–23; 8:45 am] BILLING CODE P

# DEPARTMENT OF JUSTICE

[OMB Number 1122-0003]

# Agency Information Collection Activities; Proposed eCollection eComments Requested; Annual Progress Report for the STOP Formula Grants Program

**AGENCY:** Office on Violence Against Women, Department of Justice. **ACTION:** 30-Day notice.

**SUMMARY:** The Office on Violence Against Women (OVW), Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection was previously published in the **Federal Register** on June 30, 2023, allowing a 60-day comment period.

**DATES:** Comments are encouraged and will be accepted for 30 days until September 21, 2023.

**FOR FURTHER INFORMATION CONTACT:** If you have comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Catherine Poston, Office on Violence Against Women, at 202–514– 5430 or *Catherine.poston@usdoj.gov.* 

**SUPPLEMENTARY INFORMATION:** Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

- -Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
- Évaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
  Enhance the quality, utility, and
- clarity of the information to be collected; and/or
- -Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.*, permitting electronic submission of responses.

Written comments and recommendations for this information collection should be submitted within 30 days of the publication of this notice on the following website www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting "Currently under 30-day Review-Open for Public Comments" or by using the search function and entering either the title of the information collection or the OMB Control Number 1122-0003. This information collection request may be viewed at www.reginfo.gov. Follow the instructions to view Department of Justice, information collections currently under review by OMB.

DOJ seeks PRA authorization for this information collection for three (3) years. OMB authorization for an ICR cannot be for more than three (3) years without renewal. The DOJ notes that information collection requirements submitted to the OMB for existing ICRs receive a month-to-month extension while they undergo review.

# **Overview of This Information Collection**

1. *Type of Information Collection:* Extension of a previously approved collection.

*Title of the Form/Collection:* Annual Progress Report for the STOP Formula Grants Program.

Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection: Form Number: 1122–0003. U.S. Department of Justice, Office on Violence Against Women.

2. Affected public who will be asked or required to respond, as well as a brief abstract: Affected Public: State, local and tribal governments.

Abstract: The STOP Violence Against Women Formula Grants Program was authorized through the Violence Against Women Act of 1994 (VAWA) and amended and reauthorized in 2000, 2005, 2013 and 2022. The STOP (Services, Training, Officers, and Prosecutors) Violence Against Women Formula Grant Program funding is awarded to states and territories. It enhances the capacity of local communities to develop and strengthen effective law enforcement and prosecution strategies to combat domestic violence, dating violence, sexual assault and stalking and to develop and strengthen comprehensive, holistic victim services. The grant funds must be distributed by STOP state administrators to subgrantees according to a statutory formula. The annual progress reporting form is necessary for the Attorney General and STOP Formula Grant Program grantees and subgrantees to comply with federal statutory reporting requirements. The information will be used for reports to Congress on the use of appropriated funds in support of the STOP Formula Grant Program. There are two sets of respondents-the STOP state administrators who allocate the STOP funds and the subgrantees who may include law enforcement agencies, prosecutors officers, courts, and victim services organizations.

3. *Obligation to Respond:* Required to obtain or retain a benefit.

4. Total Estimated Number of Respondents: 2,556.

5. *Estimated Time per Respondent:* One hour.

6. Frequency: Annual.

7. Total Estimated Annual Time Burden: 2,556.

8. Total Estimated Annual Other Costs Burden: \$0.

*If additional information is required, contact:* Darwin Arceo, Department Clearance Officer, Policy and Planning Staff, Justice Management Division, United States Department of Justice, Two Constitution Square, 145 N Street NE, 4W–218 Washington, DC 20530.

Dated: August 17, 2023.

#### Darwin Arceo,

Department Clearance Officer for PRA, U.S. Department of Justice.

[FR Doc. 2023–18071 Filed 8–21–23; 8:45 am] BILLING CODE 4410–14–P

# DEPARTMENT OF JUSTICE

[OMB Number 1122-0034]

# Agency Information Collection Activities; Proposed eCollection eComments Requested; STOP Formula Grant Program Match Documentation Worksheet

**AGENCY:** Office on Violence Against Women, Department of Justice. **ACTION:** 30-Day notice.

**SUMMARY:** The Office on Violence Against Women (OVW), Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection was previously published in the **Federal Register** on June 30, 2023, allowing a 60-day comment period.

**DATES:** Comments are encouraged and will be accepted for 30 days until September 21, 2023.

**FOR FURTHER INFORMATION CONTACT:** If you have comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact: Catherine Poston, Office on Violence Against Women, at 202–514– 5430 or *Catherine.poston@usdoj.gov.* 

**SUPPLEMENTARY INFORMATION:** Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

-Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

- Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
  Enhance the quality, utility, and
- clarity of the information to be collected; and/or
- —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.*, permitting electronic submission of responses.

Written comments and recommendations for this information collection should be submitted within 30 days of the publication of this notice on the following website www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting "Currently under 30-day Review—Open for Public Comments" or by using the search function and entering either the title of the information collection or the OMB Control Number 1123-0034. This information collection request may be viewed at www.reginfo.gov. Follow the instructions to view Department of Justice, information collections currently under review by OMB.

DOJ seeks PRA authorization for this information collection for three (3) years. OMB authorization for an ICR cannot be for more than three (3) years without renewal. The DOJ notes that information collection requirements submitted to the OMB for existing ICRs receive a month-to-month extension while they undergo review.

# **Overview of This Information** collection

1. *Type of Information Collection:* Extension of a previously approved collection.

2. *Title of the Form/Collection:* STOP Formula Grant Program Match Documentation Worksheet.

3. Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection: 1122–0034. U.S. Department of Justice, Office on Violence Against Women.

4. Affected public who will be asked or required to respond, as well as a brief abstract: Affected Public: State, local and Tribal governments.

*Abstract:* The STOP Violence Against Women Formula Grants Program was authorized through the Violence Against

Women Act of 1994 (VAWA) and amended and reauthorized in 2000, 2005, 2013 and 2022. The STOP (Services, Training, Officers, and Prosecutors) Violence Against Women Formula Grant Program funding is awarded to States and Territories. It enhances the capacity of local communities to develop and strengthen effective law enforcement and prosecution strategies to combat domestic violence, dating violence, sexual assault and stalking and to develop and strengthen comprehensive, holistic victim services. The grant funds must be distributed by STOP State administrators to subgrantees according to a statutory formula. The Department of Justice's Office on Violence Against Women administers the STOP Formula Grant Program funds which are awarded to States and territories to enhance the capacity of local communities to develop and strengthen effective law enforcement and prosecution strategies to combat violent crimes against women and to develop and strengthen victim services in cases involving violent crimes against women. Each State and territory must allocate 25 percent for law enforcement, 25 percent for prosecutors, 30 percent for victim services (of which at least 10 percent must be distributed to culturally specific community-based organizations), 5 percent to State and local courts, and 15 percent for discretionary distribution. VAWA provides for a 25 percent match requirement imposed on grant funds under the STOP Formula Grant Program. Thus, a grant made under this program may not cover more than 75 percent of the total costs of the project being funded. Under VAWA 2005, the State cannot require matching funds for a grant or subgrant for any Tribe, Territory, or victim service provider, regardless of funding allocation category. The State is exempted from matching the portion of the State award that goes to a victim service provider for victim services or that goes to Tribes. Territories are also exempted in full. States can receive additional waiver of match based on a petition to OVW and a demonstration of financial need. OVW will look at the time of closeout at the entities and purposes of funds and base the required match. The purpose of this information collection is to provide a worksheet for documenting the amount of matching funds required at the closeout of a specific fiscal year award under the STOP Formula Grant Program. The type of questions on the worksheet will include award number, award amount, amount of funds sub-